Position in PGEN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,083,000
New position
Shares Held
190,000
first reported quarter
Ownership
0.053%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
#62
of 208 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in PGEN
reported options exposure · as of Jun 30, 2026CallValue
$684,000
CallShares
120,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Shay Capital LLC holds $28,794,197 across 40 Biotechnology names. PGEN ranks #8 (3.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DFTX |
Definium Therapeutics, Inc.
|
80,000 | $3,763,200 | |
| 2 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
44,000 | $3,586,440 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
12,500 | $2,341,000 | |
| 4 | MANE |
Veradermics, Inc
|
19,000 | $2,335,860 | |
| 5 | BCAX |
Bicara Therapeutics Inc.
|
68,000 | $2,018,920 | |
| 6 | QURE |
uniQure N.V.
|
37,419 | $1,723,519 | |
| 7 | AVLN |
Avalyn Pharma Inc.
|
40,000 | $1,316,800 | |
| 8 | PGEN |
Precigen, Inc.
This page
|
190,000 | $1,083,000 |
All Filings in PGEN
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,083,000 | 190,000 | Shares | Sole | 2026-08-14 | |
| 2026-06-30 | $684,000 | 120,000 | Call | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||